The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention
International Journal of Neuropsychopharmacology · 2025
DOI: 10.1093/ijnp/pyaf005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Neuropsychopharmacology, 2025. Verfasst von Mustafa Tuncturk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Vaccines, Analgesics, Opioid, Drug Overdose. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mayo Clinic Research Pipeline K2R Program, Terrance and Bette Noble Foundation, NIH HHS.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Opioid use disorder (OUD) affects over 40 million people worldwide, creating significant social and economic burdens. Medication for opioid use disorder (MOUD) is often considered the primary treatment approach for OUD. MOUD, including methadone, buprenorphine, and naltrexone, is effective for some, but its benefits may be limited by poor adherence to treatment recommendations. Immunopharmacotherapy offers an innovative approach by using vaccines to generate antibodies that neutralize opioids, blocking them from crossing the blood-brain barrier and reducing their psychoactive effects. To date, only 3 clinical trials for opioid vaccines have been published. While these studies demonstrated the potential of opioid vaccines for relapse prevention, there is currently no standardized protocol for evaluating their effectiveness. We have reviewed recent preclinical studies that demonstrated the efficacy of vaccines targeting opioids, including heroin, morphine, oxycodone, hydrocodone, and fentanyl. These studies showed that vaccines against opioids reduced drug reinforcement, decreased opioid-induced antinociception, and increased survival rates against lethal opioid doses. These studies also demonstrated the importance of vaccine formulation and the use of adjuvants in enhancing antibody production and specificity. Finally, we highlighted the strengths and concerns associated with the opioid vaccine treatment, including ethical considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States.
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.
ORCID-Profile: Mustafa Tuncturk, Ming-Fen Ho
Förderung
- Mayo Clinic Research Pipeline K2R Program
- Terrance and Bette Noble Foundation
- NIH HHS
- AHRQ HHS
- the Brain & Behavior Research Foundation
- Mayo Clinic Center for Individualized Medicine
- National Institutes of Health
Zitieren
APA
Tuncturk, M., Kushwaha, S., Heider, R. M., Oesterle, T., Weinshilboum, R., & Ho, M. F. (2025). The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyaf005
Vancouver
Tuncturk M, Kushwaha S, Heider RM, Oesterle T, Weinshilboum R, Ho MF. The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention. International Journal of Neuropsychopharmacology. 2025. doi:10.1093/ijnp/pyaf005
BibTeX
@article{Tuncturk2025,
author = {Tuncturk, Mustafa and Kushwaha, Shikha and Heider, Robin M and Oesterle, Tyler and Weinshilboum, Richard and Ho, Ming-Fen},
title = {The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention},
journal = {International Journal of Neuropsychopharmacology},
year = {2025},
doi = {10.1093/ijnp/pyaf005}
}
EUVIMED